Turnstone Biologics Corp. (TSBX)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (1.43%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $0.36 +0.01 (1.41%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TSBX 0.36 +0.01(1.43%)
Will TSBX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TSBX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TSBX
Turnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?
TSBX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TSBX
Turnstone Biologics to be acquired by XOMA Royalty
Turnstone Biologics (TSBX) Agrees to Acquisition by XOMA Royalty | TSBX Stock News
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
Xoma to acquire Turnstone Biologics for $0.34 in cash per share
Turnstone Biologics Corp. Enters Merger Agreement with XOMA